Liquid Embolic Agent Market to Surpass USD 822.9 Million by 2036 as Neurovascular Treatment Adoption Accelerates Worldwide

The global liquid embolic agent market is experiencing rapid expansion driven by increasing neurovascular disorder prevalence, growing physician confidence in minimally invasive interventions, and broader regulatory approvals. Advances in embolization technologies, expanding reimbursement coverage, and rising healthcare investments in emerging economies are further strengthening market demand.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=12264

According to Fact.MR, the global liquid embolic agent market is projected to grow from USD 308.7 million in 2026 to USD 822.9 million by 2036, registering a CAGR of 10.3%. The market is expected to create an absolute dollar opportunity of USD 514.1 million during the forecast period.

Executive Summary & Stakeholder Insights

Key Market Highlights

• Market valued at USD 279.9 million in 2025.
• Expected to reach USD 308.7 million in 2026.
• Forecast to surpass USD 822.9 million by 2036.
• Projected CAGR stands at 10.3% from 2026 to 2036.
• Non-Adhesive Liquid Embolic Agents will remain the leading product category in 2026.
• Polymer-Based Systems will dominate the composition segment.
• Neurovascular Disorders will generate the highest application demand.
• Hospitals will remain the leading end-use segment.
• Catheter-Based Delivery Systems will lead the delivery technique category.
• India (12.2%) and China (11.3%) represent the fastest-growing country markets.

Competitive Landscape & Entity Mapping

Leading Companies and Estimated Market Positioning

• Medtronic plc (16-18% share) - Global leader with strong embolization portfolio and expanding geographic reach.
• Johnson & Johnson (CERENOVUS) (12-15%) - Focused on neurovascular innovation and clinical evidence generation.
• Terumo Corporation (10-13%) - Strong presence in catheter-based intervention technologies.
• B. Braun SE (8-11%) - Expanding market access through distribution partnerships.
• Boston Scientific Corporation (6-9%) - Growing participation in vascular intervention solutions.
• Meril Life Sciences, Balt Group, GEM Srl, Sirtex Medical, and INVAMED maintain competitive positions across regional and specialty segments.

Segment-Wise Performance Analysis

By Product - Non-Adhesive Liquid Embolic Agents
Non-adhesive liquid embolic agents will lead the market due to broad clinical acceptance, strong physician familiarity, and extensive reimbursement support across major healthcare systems.
By Composition - Polymer-Based Systems
Polymer-based systems remain the largest composition segment, supported by extensive clinical evidence, established treatment pathways, and widespread adoption in neurovascular interventions.
By Application - Neurovascular Disorders
Neurovascular disorders represent the primary application area as embolic agents play a critical role in treating arteriovenous malformations, intracranial aneurysms, and dural arteriovenous fistulas.
By End Use - Hospitals
Hospitals continue to dominate demand due to advanced imaging infrastructure, specialist expertise, and higher volumes of complex neurovascular procedures.
By Delivery Technique - Catheter-Based Delivery
Catheter-based delivery systems lead the market because they offer precise embolization, procedural efficiency, and compatibility with minimally invasive treatment protocols.

Regional Growth Highlights

• India: 12.2% CAGR driven by expanding healthcare access, tertiary care infrastructure, and rising specialty treatment adoption.
• China: 11.3% CAGR supported by hospital expansion and increasing diagnosis rates.
• Brazil: 10.5% CAGR fueled by public healthcare procurement and private sector investments.
• United States: 9.7% CAGR driven by strong payer coverage and advanced neurovascular treatment adoption.
• United Kingdom: 9.1% CAGR supported by NHS specialty treatment networks.
• Germany: 8.2% CAGR due to structured reimbursement systems and healthcare modernization.
• Japan: 7.6% CAGR driven by aging demographics and specialty care demand.

Explore the Full Research Study & Forecast: https://www.factmr.com/report/liquid-embolic-agent-market

Frequently Asked Questions

What is driving growth in the liquid embolic agent market?
Rising neurovascular disorder prevalence, expanding clinical evidence, and increasing reimbursement support are accelerating global market growth.
How large will the liquid embolic agent market become by 2036?
The market is projected to reach USD 822.9 million by 2036, growing at a CAGR of 10.3%.
Which product segment leads the market?
Non-Adhesive Liquid Embolic Agents lead the market due to strong clinical adoption and broad physician acceptance.
Why is India emerging as a key growth market?
India is projected to grow at 12.2% CAGR because of expanding healthcare infrastructure, increasing specialty care access, and supportive government healthcare initiatives.
Which application generates the highest demand?
Neurovascular disorders account for the largest share of demand, driven by growing treatment volumes for aneurysms and arteriovenous malformations.
Who are the leading companies in the liquid embolic agent market?
Medtronic, Johnson & Johnson (CERENOVUS), Terumo Corporation, B. Braun SE, and Boston Scientific are among the industry's leading players.

Market Outlook

The liquid embolic agent market is evolving into a high-growth neurovascular intervention segment supported by technological innovation, expanding clinical evidence, and growing healthcare investments. Companies that strengthen physician education, expand reimbursement access, and establish strong distribution networks in emerging markets are expected to gain a competitive advantage through 2036.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/checkout/12264

To View Related Report:

GLP-1 Companion Products Market https://www.factmr.com/report/glp-1-companion-products-market
Automated NGS Library Preparation Market https://www.factmr.com/report/automated-ngs-library-preparation-market
DNA and RNA Sample Preparation Market https://www.factmr.com/report/dna-and-rna-sample-preparation-market
Biodegradable Dressing Market https://www.factmr.com/report/biodegradable-dressing-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.